Dynavax Melanoma Trial
Both males and females
18 years to 70 years
Closed: follow-up continuing
This trial is designed to evaluate the safety, tolerability, and preliminary efficacy of intra-tumour injections of SD-101 in combination with intravenous Keytruda (pembrolizumab) in patients with metastatic melanoma.
Patients can have progressed on prior treatment with Keytruda or other anti-PD1 therapy or can have not yet received Keytruda/other anti-PD1 therapy. More information can be found here.